Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Measles is a highly infectious viral disease which can lead to serious complications. In high income regions of the world such as Western Europe, it causes death in at least 1 in 5000 cases, but as many as 1 in 100 will die in the poorest regions of the world.

Worldwide, measles is still a major cause of death, especially among children in resource-poor countries. In 2011, 158,000 people died of measles – an average of 432 every day. However, over the last twenty years vaccination has dramatically reduced the number of deaths from measles. Since 1990 (when measles killed 872,000 people), over one in 5 of all child deaths averted have been due to measles vaccination.

In the short film below, experts talk about measles and its complications, and the importance of the MMR vaccine.

Read more about the symptoms, how it is passed on and how the MMR vaccine protects people on the Vaccine Knowledge Project website.

Similar stories

Human challenge trial launches to study immune response to COVID-19

COVID-19 Vaccinology

Though the COVID-19 pandemic has now been active for a year, not much is known about what happens when people who have already had COVID-19 are infected for a second time.

Alternating vaccines trial expands to include two additional vaccines

COVID-19 Clinical Trials Vaccinology

Researchers running the Com-Cov study, launched in February to investigate alternating doses of the Oxford-AstraZeneca vaccine and the Pfizer vaccine, have today announced that the programme will be extended to include the Moderna and Novavax vaccines in a new study.

UK and EU regulators conclude benefits of vaccination continue to outweigh the risks

COVID-19 Vaccinology

Medical regulators in the UK and Europe have announced their conclusions from their reviews of very rare cases of unusual blood clots in people who have received the Oxford-AstraZeneca coronavirus vaccine.

AstraZeneca publish primary analysis from US trial of coronavirus vaccine

COVID-19 Vaccinology

Our partners AstraZeneca have today announced the high-level results from the primary analysis of their Phase III trial of the ChAdOx1 nCoV-19 coronavirus vaccine in the US. They confirm that the vaccine efficacy is consistent with the interim analysis results announced on Monday 22 March 2021.

USA, Chile and Peru interim trial data show Oxford-AstraZeneca vaccine is safe and highly effective

COVID-19 Vaccinology

- Oxford-AstraZeneca coronavirus vaccine 79% effective against symptomatic COVID-19 overall - Vaccine 100% effective against severe or critical symptomatic COVID-19 - No safety concerns reported

Celebrating Early Careers Researchers on International Women's Day

General

In these short interviews, Anna Kordala and Jane Millar talk about the research they do at the Department of Paediatrics.